NFKB1 and Miyoshi myopathy: Moreover, while IMiDs and proteasome inhibitors have been shown to impact NF-κB signalling, these agents have broad biological activities, lack specificity for the NF-κB pathway, and, importantly, afford their clinical effects in MM via NF-κB-independent mechanisms [1,16,17].